Microfluidic biochips have revolutionized the traditional biological, biochemical and biomedical experimental processes. Noticeable merits of microfluidic biochips over traditional laboratory platforms include: (1) greatly saving the assay cost by reducing expensive samples/reagents to nano-liter or pico-liter volume, (2) effectively integrating the automatic control logic for reduced human intervention and labor cost, (3) significantly increasing sensitivity, accuracy and throughput, (4) essentially facilitating portability for point-of-care diagnostics, and (5) naturally enabling microscale assays (e.g., single-cell culture, capture and analysis) that are infeasible by traditional macroscale approaches. According to Research and Markets, the global biochips market is expected to grow at a CAGR of 18.6% from 2012 to 2018, and will reach $11.4 billion by 2018. Microfluidic biochips have many promising applications, such as diagnostics and treatment, drug discovery and development, biological research, forensic analysis, agriculture, environmental sensors, food inspection, etc. This talk will introduce the fundamental microfluidics technology for biochips, as well as the electronic design automation (EDA) solutions for enabling microfluidic large-scale integration, which will boost the coming age of real-time health monitoring along with personalized preventive healthcare.